Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (7898)	10/26/2001 6:12:05 PM
From: Salt'n'Peppa	Read Replies (1) \| Respond to of 14101

DMX should take a serious look at buying this San Diego facility. Another biotech that I have been watching for a long time (and thankfully never bought) is Matrix Pharma (MATX: Nasdaq). Following FDA denial of their novel Cancer treatment, they are selling their manufacturing plant in San Diego. It is fully equipped and has a full complement of trained personnel, ready to cook up any potion asked for. Looks like they are asking $11 million for it. Could be a nice buy if we get FDA Pennsaid approval. ca.us.biz.yahoo.com Also interesting is that MATX is looking to the EU for approval of their Intradose Gel following the FDA failure. Even more interesting is that MATX is not going through the "Mutual Recognition" process that DMX is pursuing. {{{``Matrix decided to pursue centralized approval in Europe when the EMEA confirmed that IntraDose qualified for this process,'' said Michael Casey, Chairman, President and CEO. ``We felt that filing through the centralized procedure may streamline the registration process in Europe compared to the older mutual recognition system,'' he said }}} ca.us.biz.yahoo.com I don't think RK was aware of a centralized procedure. Cheers, S&P